Abstract:Objectives We aim to explore the incidence and risk factors of AF, dangerous ventricular arrhythmias and bradyarrhythmia in patients with HCM, and improve the awareness of clinicians on hypertrophic cardiomyopathy (HCM) associated with life-threatening arrhythmias. Methods We retrospectively collected the clinical data of 86 unrelated patients diagnosed as HCM in our hospital from January 2009 to January 2012, including each patient9s personal characteristics, clinical manifestations, echocardiography, 12-lead electrocardiography(ECG), 24 h Holter ECG monitoring, coronary angiography, left ventricular angiography and related treatment. Results 1. In 86 patients with HCM, male and female patients were 56 and 30, respectively, and mean age was 58.4±14.3 years. 2. 21 patients (24.4%) had documented AF, 7 patients with paroxysmal AF and 14 patients with chronic AF. 72 patients (85.7%) had premature ventricular contractions (PVCs), 36 patients (41.9%) had PVCs with Low grade ≥3, and 22 patients (25.6%) had non-sustained ventricular tachycardia (NSVT). eight patients (9.3%) had sick sinus syndrome (SSS), 11 patients (12.8%) had atrioventricular block (AVB) and nine patients (10.5%) had atrial fibrillation with slow ventricular rate and long RR interval (RR interval >2.0 s). 3. The mean age at examination was 64.1±11.0 years in patients with AF, older than those with sinus rhythm (56.6±14.8 years) (p=0.037). Left atrial diameter (LAD) was greater in patients with AF than those without AF (45.3±5.2 mm vs 40.2±5.2 mm) (p<0.01). There were 8 cases (38.1%) in NYHA classes III and IV in AF group, more than those without AF (6.2%, p=0.001). And left ventricular ejection fraction (LVEF) in AF group was lower than those without AF (64.8±9.7% vs 69.4±8.1%, p=0.036). 4. Maximum left ventricular wall thickness (MLVWT) and LAD was greater in patients with dangerous ventricular arrhythmias (B group) than in patients without dangerous ventricular arrhythmias (A group) (23.1±5.4 mm vs 20.2±4.9 mm and 42.8±5.2 mm vs 40.4±5.8 mm, p=0.009 and 0.048, respectively). The incidence of AF in B group was significantly higher than in A group (36.1% vs 16.0%, p<0.05). 5. In patients with pacemaker implantation, the age (mean 67.6±7.4 years) was older than those without pacemaker implantation (mean 55.5±14.1 years, p=0.01). LVEF in patients with pacemaker implantation was significantly lower than in patients without pacemaker implantation (64.0±10.0% vs 69.3±8.1%, p=0.024). And the incidence of AF in patients with pacemaker implantation was significantly higher than in patients without pacemaker implantation (52.9% vs 17.4%, p<0.05). Conclusions Our study showed the incidence of arrhythmias in patients with HCM, including AF, dangerous ventricular arrhythmias and bradyarrhythmia, was quite high. And the incidence of AF and bradyarrhythmia was positively correlated with age increasing. The occurrence of AF was significantly associated with LAD, cardiac dysfunction and age. The prevalence of dangerous ventricular arrhythmias was 41.9%, and its occurrence was associated with MLVWT and LAD. LVEF was significantly decreased in patients with pacemaker implantation. The prevalence of AF in patients with dangerous ventricular arrhythmias and bradyarrhythmia was much higher than others without dangerous ventricular arrhythmias and bradyarrhythmia. Therefore, AF might play an important role in the prognosis of HCM patients.

Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy

Prevalence of cardiovascular comorbidities among hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate

Characterizing disease burden and health care resource utilization in patients with hypertrophic cardiomyopathy: a nationwide real-world study in Finland

Temporal Trends, Prevalence, Predictors, and Outcomes of Heart Failure in Patients with Hypertrophic Cardiomyopathy in the United States: Insights from the National Inpatient Sample

Role of advanced CMR features in identifying a positive genotype of hypertrophic cardiomyopathy

Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy

Electrophysiological Characterization of Subclinical and Overt Hypertrophic Cardiomyopathy by Magnetic Resonance Imaging-Guided Electrocardiography

Re-evaluating the Incidence and Prevalence of Clinical Hypertrophic Cardiomyopathy

Clinical History of Patients with Hypertrophic Cardiomyopathy-How to Improve the Initiation Process of the Diagnosis?

Clinical characteristics and burden of non-obstructive hypertrophic cardiomyopathy: a real-world survey in Italy and Spain

Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy

Long-term clinical outcomes in patients with hypertrophic cardiomyopathy versus hypertensive heart disease

Hypertrophic cardiomyopathy and atrial fibrillation: the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology

Prognosis of Patients with Familial Hypertrophic Cardiomyopathy: A Single-Center Cohort Study with Ten-Year Follow-Up by Propensity Score Matching Analysis

Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy

Machine Learning in Hypertrophic Cardiomyopathy: Nonlinear Model From Clinical and CMR Features Predicting Cardiovascular Events

Combined right and left ventricular mechanical dispersion enhance the arrhythmic risk stratification in hypertrophic cardiomyopathy

PREVALENCE AND RELATED FACTORS OF ARRHYTHMIAS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

Long Term Follow-Up Results of 199 Patients with Hypertrophic Cardiomyopathy

Nationwide trends in utilization and safety of ventricular arrythmia ablation in patients with hypertrophic cardiomyopathy

Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers